Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
New York, New York--(Newsfile Corp. - November 13, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ:
New York, New York--(Newsfile Corp. - November 13, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities o
New Orleans, Louisiana--(Newsfile Corp. - November 12, 2020) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they
New York, New York--(Newsfile Corp. - November 11, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities o
New York, New York--(Newsfile Corp. - November 10, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q3 2020 Results - Earnings Call Transcript
01:12am, Saturday, 07'th Nov 2020
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q3 2020 Results - Earnings Call Transcript
New York, New York--(Newsfile Corp. - November 6, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: B
New York, New York--(Newsfile Corp. - November 6, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of
2 Healthcare Stocks That Could Double Your Money
07:07am, Friday, 06'th Nov 2020
Patient investors could double their money in these two stocks that the market has temporarily cast aside.
How BioMarin Beat Expectations in Q3
06:02am, Friday, 06'th Nov 2020
The biotech managed to overcome headwinds caused by the COVID-19 pandemic.
BioMarin Pharmaceutical Hikes Earnings Guidance; Sales Beat Views
04:32pm, Thursday, 05'th Nov 2020
BMRN stock rose after BioMarin Pharmaceutical late Thursday hiked its earnings guidance for the year. The drug company lowered his sales outlook, but third-quarter sales beat expectations.
New York, New York--(Newsfile Corp. - November 4, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between
New York, New York--(Newsfile Corp. - November 4, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: B
New York, New York--(Newsfile Corp. - November 4, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of
Good News For BioMarin Pharmaceutical Comes With Caveat For Wary Investors
11:04am, Tuesday, 03'rd Nov 2020
BioMarin Pharmaceutical announced the FDA accepted its new drug application for a proposed treatment for dwarfism, but BMRN stock dipped as investors wary after FDA disappointment in August. The post
